PTK2 and neoplasm: Given that our data suggest that low EC-pY397-FAK expression levels with low BVD are associated with a better outcome than low EC-pY397-FAK expression levels with high BVD, future testing of vascular-disrupting agents in low EC-pY397-FAK expression levels with high BVD may provide added benefit and identify a group of patients who would benefit from targeting tumor blood vessels.